Effect of repeated treatment with milnacipran on the central dopaminergic system

Polish Journal of Pharmacology

Volumn 52, Issue 2, 2000, Pages 83-92

  Rogóz, Zofia ^a   Margas, Wojciech ^a   Dlaboga, Daniel ^a   Góralska, Marta ^a   Dziedzicka Wasylewska, Marta ^a   Maj, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adaptative changes in dopaminergic system; Milnacipran; Rats; Repeated treatment

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BRAIN RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; MILNACIPRAN; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; GROOMING; HYPERACTIVITY; LIGAND BINDING; LIMBIC SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; RAT; RECEPTOR DENSITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; AMPHETAMINE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM; CYCLOPROPANES; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; GROOMING; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPIPERONE; STEREOTYPED BEHAVIOR; TETRAHYDRONAPHTHALENES;

EID: 0034023673     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Ansseau M., von Frenckell R., Mertens C., de Wilde J., Botte L., Devoitille J.-M., Evrard J.-L., De Nayer A., Darimont P., Dejaiffe G., Mirel J., Meurice E., Parent M., Couzinier J.-P., Demarez J.-P., Serre C.: Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology, 1989, 98, 163-168.
2. Ansseau M., von Frenckell R., Rapart P, Mertens C., de Wilde J., Bottle L., Devoitille J.-M., Evrard J. L., De Nayer A., Koch-Bourdouxhe S., Darimont P., Lecoq A., Mirel J., Couzinier J.-P., Demarez J.-P., Serre C.: Controlled comparison of milnacipran (F 2207) 200 mg and amitriptyline in endogenous depressive inpatients. Hum. Psychopharmacol. Clin. Exp., 1989, 4, 221-227.
3. Assie M. B., Charvenon M., Palmier C., Puzzo C., Moret C., Briley M.: Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology, 1992, 31, 149-155.
4. Bouthenet M. L., Souil M. P., Martres P., Sokoloff P., Giros B., Schwartz J. C.: Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res., 1991, 564, 203-219.
5. Briley M., Moret C.: Effect of milnacipran on the serotonin and noradrenaline reuptake processes: fundamental and clinical implications. XXIst CINP Congress, Glasgow, July 12-16, 1998, Abstr. SM 1002.
6. Camacho-Ochoa M., Walker E. L., Evans D. L., Piercey M. F.: Rat brain binding sites for pramipexole, a clinically useful DS-preferring dopamine agonist. Neurosci. Lett., 1995, 196, 97-100.
7. Clerc G. E., Pagot R., Bouchard J. M., Quales J., Guibert M., Assicot M., Guillard A., Cottin M., Dachary J. M., Bezaury J. P., Parmentier G., Gresle P., Von Frenckell R., Serre C.: Therapeutic contribution of milnacipran and clomipramine during a 3-month treatment: results of a comparative study. Psychiat. Psychobiol., 1990, 5, 137-143.
8. Daly S. A., Waddington J. L.: Behavioural effects of the putative D3 dopamine receptor agonist 7-OH-DPAT in relation to other D2-like agonist. Neuropharmacology, 1993, 32, 509-510.
9. Damsma G., Bottema T., Westerink B. H., Tepper P. G., Dijkstra D., Pugsley T. A., MacKenzie R. G., Heffner R. G., Wilkstrom H.: Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur. J. Pharmacol., 1993, 249, R9-R10.
10. Dellini-Stula A., Vassout A.: Modulation of dopamine behavioural responses by antidepresants. Effects of single and repeated treatment. Eur. J. Pharmacol., 1979, 58, 443-451.
11. DeMontis G. M., Devoto P., Gessa G. L., Meloni D., Porcella A., Saba P., Serra G., Tagliamonte A.: Chronic imipramine reduces 3H-SCH23390 binding and dopamine sensitive adenylate cyclase in the limbic system. Eur. J. Pharmacol., 1989, 167, 299-303.
12. Fallon J. H., Loughlin S. E., Ribak C. E.: The islands of Calleja complex of rat basal forebrain. III. Histochemical evidence for striatopallidal system. J. Comp. Neurol., 1983, 218, 91-120.
13. Hillefors-Berglund N., Von Euler G.: Pharmacology of dopamine D3 receptors in the islands of Calleja of the rat using quantitive receptor autoradiography. Eur. J. Pharmacol., 1994, 261, 179-183.
14. Kasper S., Pletan Y., Solles A., Tournoux A.: Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int. Clin. Psychopharmacol., 1996, 11, Suppl. 4, 35-39.
15. Klimek V., Maj J.: Repeated administration of antidepressants enhances agonist affinity for mesolimbic D2 receptors. J. Pharm. Pharmacol., 1989, 41, 555-558.
16. Klimek V., Nielsen M.: Chronic treatment with antidepressants decreases the number of [3H]SCH23390 binding sites in the rat striatum and the limbic system. Eur. J. Pharmacol., 1987, 139, 163-169.
17. Leinonen E., Lepola U., Koponen H., Mehtonen O. P., Rimon R.: Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiat. Scand., 1997, 96, 497-504.
18. Lévesque D., Diaz J., Pilon C., Mertres M.-P., Giros B., Souil E., Schott D., Morgot J.-L., Schwartz J. C., Sokoloff P.: Identification, characterization and localization of the dopamine D3 receptor in rat brain using 7-[3H]-hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Nat. Acad. Sci. USA, 1992, 89, 8155-8159.
19. 1,-adrenergic, dopamine and serotonin systems. J. Neural Transm., 1999, 106, 197-211.
20. Maj J., Bijak M., Dziedzicka-Wasylewska M., Rogoż R., Rogóż Z, Skuza G., Tokarski K.: The effects of paroxetine given repeatedly on the 5-HT receptor sub-populations in the rat brain. Psychopharmacology, 1996, 127, 73-77.
21. Maj J., Dziedzicka-Wasylewska M., Rogoż R., Rogóż Z.: Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain. Eur. J. Pharmacol., 1998, 351, 31-37.
22. Maj J., Dziedzicka-Wasylewska M., Rogoż R., Rogóż Z., Skuza G.: Antidepressant drugs given repeatedly change the binding of the dopamine D2 agonist, [3H]N-0437, to dopamine D2 receptors in the rat brain. Eur. J. Pharmacol., 1996, 304, 49-54.
23. 1,-adrenergic, dopaminergic and serotonergic receptors in rat brain. Hum. Psychopharmacol.-Clin. Exp., 1999, 14, 333-344.
24. Maj J., Mogilnicka E., Klimek V., Kordecka-Magiera A.: Chronic treatment with antidepressants: potentiation of clonidine-induced aggression in mice via noradrenergic mechanism. J. Neural Transm., 1981, 52, 189-197.
25. 2 agonists. J. Neural Transm., 1989, 76, 29-38.
26. 2A systems. J. Neural Transm., 2000, in press.
27. Maj J., Rogóż Z., Skuza G.: Antidepressant drugs given repeatedly increase the behavioural effects of methoxamine. Hum. Psychopharmacol.-Clin. Exp., 1989, 4, 65-70.
28. Maj J., Rogóż Z., Skuza G., Sowińska H.: Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. J. Pharm. Pharmacol., 1984, 36, 127-130.
29. Maj J., Rogóż Z., Skuza G., Sowińska H.: The effects of repeated treatment with antidepressant drugs on the action of D-amphetamine and apomorphine in rats. In: Neuropharmacology '85. Eds. Kelemen K., Magyar K., Vizi E. S., Akadémiai Kiadó, Budapest, 1985, 133-139.
30. 2 agonist. J. Neural Transm.-Gen. Sect., 1989, 78, 1-8.
31. Martin-Iverson M. T., Leclere J.-F., Fibiger H. C.: Cholinergic-dopaminergic interactions and the mechanism of action of antidepressants. Eur. J. Pharmacol., 1983, 94, 193-201.
32. 1 antagonist SCH 23390. Psychopharmacology, 1984, 82, 409-410.
33. 2 antagonists SCH 23390 and metoclopramide. Eur. J. Pharmacol., 1985, 108, 305-308.
34. Montgomery S. A., Prost J. F., Solles A., Briley M.: Efficacy and tolerability of milnacipran: an overview. Int. Clin. Psychopharmacol., 1996, 11, Suppl. 4, 47-51.
35. Moret C., Charveron M., Finberg J. P. M., Couzinier J.-P., Briley M.: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-amino-methyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology, 1985, 24, 1211-1219.
36. Muth E. A., Haskins J. T., Moyer J. A., Husbands G. E. M., Nielsen T., Sigg E. B.: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol., 1986, 35, 4493-4497.
37. Muth E. A., Moyer J. H., Haskins J. T., Andree T. H., Husbands G. E. M.: Biochemical, neurophysiological and behavioural effects of Wy-45,233 and other identified metabolites of the antodepressant venlafaxine. Drug Develop. Res., 1991, 23, 191-199.
38. Neliat G., Bodinier M.-C., Panconi E., Briley M.: Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the β-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology, 1996, 35, 589-593.
39. Paxinos G., Watson C.: The Rat Brain Stereotaxic Coordinates. Academic Press, Sydney, 1986.
40. Peroutka S. J., Snyder S. H.: Chronic antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science, 1980, 210, 88-90.
41. Puozzo C., Deprez D., Reh C., Horta N., Schmidt B., Zorza G., Nguyen L., Filaquier C.: Study on the influence of milnacipran on the activity of cytochrome P450 isoenzymes in healthy volunteers. XXIst CINP Congress, Glasgow, July 12-16, 1998, Abstr. PM 02083.
42. Puozzo C., Leonard B. E.: Pharmacokinetics of milnacipran in comparison with other antidepressants. Int. Clin. Psychopharmacol., 1996, 11, Suppl. 4, 15-27.
43. Rigney U., Stanley N., Briley M., Hindmach J.: Pharmacodynamics of milnacipran in young and elderly volunteers. XXIst CINP Congress, Glasgow, July 12-16, 1998, Abstr. PM 02084.
44. Rogóż Z., Skuza G., Maj J.: Pharmacological profile of milnacipran, a new antidepresant, given acutely. Pol. J. Pharmacol., 1999, 51, 317-322.
45. Serre C., Clerc G., Escande M., Feline A., Gineste D., Tignol J., Von Amerongen P.: An early clinical trial of milnacipran, a potential fourth generation antidepressant. Curr. Ther. Res., 1986, 39, 156-164.
46. 1 agonist SKF 38393. Pol. J. Pharmacol., 1989, 41, 421-429.
47. 2 receptor. Eur. J. Pharmacol., 1992, 225, 331-337.
48. 3 as a target for neuroleptics. Nature, 1990, 347, 146-151.
49. Spencer C. M., Wilde M. I.: Milnacipran. A review of its use in depression. Drugs, 1995, 56, 405-427.
50. Spyraki C., Fibiger H. C.: Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur. J. Pharmacol., 1981, 74, 195-206.
51. 2 receptors. Neuropsychopharmacology, 1986, 5, 455-463.
52. Steen A., Den Boer J. A.: A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int. Clin. Psychopharmacol., 1997, 12, 269-281.
53. Stenger A., Couzinier J.-P., Briley M.: Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane hydrochloride (F 2207), a new potential antidepressant. Psychopharmacology, 1987, 91, 147-153.